RetCAD™ 2.0 version approved for use in Australia and New Zealand

RetCAD™ 2.0 version approved for use in Australia and New Zealand

Published On: October 13th, 2022

We are pleased to announce that the RetCAD™ 2.0 release has been approved for use by TGA, Australia's regulatory authority, opening up new distribution possibilities in Australia and New Zealand.

New RetCAD™ update comes with a fully integrated patient report supported with international standards for disease classification, such as the ICDR (International Clinical Diabetic Retinopathy) for Diabetic Retinopathy (DR) and AREDS (Age-Related Eye Disease Study) for Age-related Macular Degeneration (AMD). It also provides a clear fact-based recommendation for patients with worrying eye-disease symptoms. The intuitive visual format of the report, including heat maps and score diagrams, allows quick and easy interpretation of the results by the eye care providers. The simplified presentation of eye examination can be easily discussed and shared with the patient, significantly improving the patient's education and compliance. 

RetCAD™ uses state-of-the-art deep learning and computer vision technology utilizing a large amount of retinal images in order to provide precisely quantified clinical evidence. The software assists eye care specialists in early diagnosis and grading of vision threatening diseases, such as Age-related Macular Degeneration (AMD) and Diabetic Retinopathy (DR). Simplified visualization of the scan analysis with heat maps help improve patient engagement and prevent severe eyesight problems and blindness.

Share This Story, Choose Your Platform!